最新消息
I-MAB Filed 2023 Annual Report on Form 20-F
2024.04.30
ROCKVILLE, Md. , April 30, 2024 /PRNewswire/ -- I-Mab (the "Company") (NASDAQ: IMAB ), a U.S. -based, global biotech company, exclusively focused on the development and potential commercialization of highly differentiated immunotherapies for the treatment of cancer, today announced that it has
ROCKVILLE, Md. , April 5, 2024 /PRNewswire/ -- I-Mab (NASDAQ: IMAB ), a U.S. -based, global biotech company, exclusively focused on the development and potential commercialization of highly differentiated immunotherapies for the treatment of cancer, today announced that management will present at
ROCKVILLE, Md. , April 2, 2024 /PRNewswire/ -- I-Mab (the " Company ") (NASDAQ: IMAB ) a U.S. -based, global biotech company, exclusively focused on the development and potential commercialization of highly differentiated immunotherapies for the treatment of cancer, today announced that